Three years after leaving Biogen, Alpna Seth takes the spotlight with $73M for her neuro startup
When Alpna Seth returned to the US from Europe in 2017 — where she was tasked with setting up Biogen’s biosimilars business from the ground up — she knew she was ready to leave her 19-year tenure behind and lead her own startup as CEO. Once she landed in the Bay Area, she called George Scangos, her just-retired boss.
“He said, ‘You know, I’m setting up Vir,’” she recalled. “We have a lot of money, you have experience setting up new businesses — why don’t you come join me as chief operating officer?”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.